Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 13, Number 4—April 2007


Endpoints for Lymphatic Filariasis Programs

Caroline A. Grady*, Madsen Beau de Rochars†, Abdel N. Direny†, Jean Nicolas Orelus†, Joyanna Wendt*, Jeanne Radday*, Els Mathieu*, Jacquelin M. Roberts*, Thomas G. Streit‡, David G. Addiss*, and Patrick J. Lammie*Comments to Author 
Author affiliations: *Centers for Disease Control and Prevention, Atlanta, Georgia, USA; †Hopital Ste. Croix, Leogane, Haiti; ‡University of Notre Dame, Notre Dame, Indiana, USA;

Main Article


Drug coverage for Leogane Commune, Haiti

2000 2001 2002 2003 2004
No. treated* 74,000 55,000 94,000 102,000 122,000
Reported coverage† 69% 50% 84% 89% 104%
Surveyed coverage‡ 71% NA 79% NA NA
Adverse events§ 23% 16% 9% 8% 3%

*Based on tally counts from distribution posts.
†Using 108,000 as the total population of Leogane determined by cluster survey in 2000, adjusted for annual population growth.
International Data Base (IDB): available from
‡Published data (7,8)
§Based on the number of persons who reported to distribution posts with reportts adverse events as a percentage of the reported coverage. See reference (9) for a more detailed discussion of adverse events associated with the first round of mass drug administration..

Main Article

Top of Page The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO